Bibliography
- ROSENBERG SA, AEBERSOLD P, CORNETTA K et al.: Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl. j. Med. (1990) 9:570–578.
- CHAN LMC, COUTELLE C, THEMIS M: A novel human suspension culture packaging cell line for production of high-titre retroviral vectors. Gene Therapy (2001) 8:697–703.
- PIZZATO M, MERTEN OW, BLAIR ED, TAKEUCHI Y: Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors. Gene Therapy (2001) 8:737–745.
- PASTORINO S, MASSAZZA S, CILLI M, VARESIO L, BOSCO MC: Generation of high-titre retroviral vector-producing macrophages as vehicles for in vivo gene transfer. Gene Therapy (2001) 8:431–441.
- LOGG CR, TAI C-K, LOGG A, ANDERSON WF, KASAHARA N: A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum. Gene Therapy (2001) 12:921–932.
- MACDONALD C, WALKERS, WATTS M, INGS S, LINCH DC, DEVEREUX S: Efect of changes in expression of the amphotropic retroviral receptor PIT-2 on transduction efficiency and viral titer: implications for gene therapy. Hum. Gene Therapy (2001) 11:587–595.
- UCKERT W, WILLYMSKY G, PEDERSEN FS, BLANKENSTEIN T, PEDERSEN L: RNA Levels of human retrovirus receptors PIT1 and PIT2 do not correlate with infectibility by three retroviral vector pseudotypes. Hum. Gene Therapy (1998) 9:2619–2627.
- GRABARCZYK P, GRYSKA K, WYSOCKI P, MACKIEWICZ A: Improving the retroviral vector (RV) systems for immunotherapy of cancer. Adv. Exp. Med. Biol. (2001) 495:389–392.
- UCKERT W, BECKER C, GLADOW M, et al.: Efficient gene transfer into primary human CD8+T lymphocytes by MuLV-10A1 retrovirus pseudotype. Hum. Gene Therapy (2000) 11:1005–1014.
- ENGELSTADTER M, BUCHHOLZ CJ, BOBKOVA M et al.: Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins. Gene Therapy (2001) 8:1202–1206.